Trading Signals: BSX Stock Price Prediction and Forecast (Mon. Mar. 17, 2014 - Wed. Sep. 27, 2023)(Boston Scientific Corporation)
| BSX latest price $23.9000 (0.08%) ($23.6000 - $24.0400) on Fri. Jan. 20, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 1.48% (three month average) | RSI | 86 | Latest Price | $23.9000(0.08%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | BSX advances 0.3% a day on average for past five trading days. | Weekly Trend | BSX advances 4.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support BSX advance at 0% a week (0% probability) DIA(66%) XHB(52%) GDXJ(15%) GDX(11%) SIL(11%) | Factors Impacting BSX price | BSX will decline at least -0.74% in a week (0% probabilities). EMHY(-8%) UUP(-7%) SHY(-5%) INDA(-4%) PCY(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -0.74% (StdDev 1.48%) | Hourly BBV | 0 () | Intraday Trend | -0.1% | | | |
|
5 Day Moving Average | $23.88(0.08%) | 10 Day Moving Average | $23.45(1.92%) | 20 Day Moving Average | $22.65(5.52%) | To recent high | -0.1% | To recent low | 19% | Market Cap | $34.158b | | | | Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease, and other cardiovascular disorders including structural heart conditions. The Rhythm Management segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal, and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA. |